Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03697408 · ClinicalTrials.gov registry record · Phase 1
Itacitinib + Everolimus in Hodgkin Lymphoma
A Phase 1 study of Classical Hodgkin Lymphoma, sponsored by University of Pennsylvania.
- Active
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT03697408: Active Phase 1 study of Classical Hodgkin Lymphoma, sponsored by University of Pennsylvania.
NCT03697408 is a Phase 1 study of Classical Hodgkin Lymphoma that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 23 participants, below the 77-participant average among 8 other Classical Hodgkin Lymphoma trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03697408, a Phase 1 study of Classical Hodgkin Lymphoma, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, single-group, Phase I/II study of itacitinib in combination with everolimus in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL).
Primary Outcome
Evaluate the efficacy of itacitinib in combination with everolimus in subjects with relapsed or refractory cHL as demonstrated by complete response (CR) rate, defined as the percentage of subjects achieving CR as their best response.
Conditions Studied
Interventions
- DRUG Everolimus
- DRUG Itacitinib
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-02-11 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What the registry record for NCT03697408 still lists
NCT03697408 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 77-participant average among 8 other Classical Hodgkin Lymphoma trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Classical Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Everolimus is the first listed.
NCT03697408 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03697408 about?
NCT03697408 is a clinical study titled "Itacitinib + Everolimus in Hodgkin Lymphoma". This is an open-label, single-group, Phase I/II study of itacitinib in combination with everolimus in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL).
What is the current status of trial NCT03697408?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2019-02-11. Estimated completion is 2027-06.
What conditions does trial NCT03697408 study?
This clinical trial studies the following conditions: Classical Hodgkin Lymphoma.
What interventions are being tested in trial NCT03697408?
The interventions under investigation include: Everolimus (DRUG), Itacitinib (DRUG).
Who is sponsoring clinical trial NCT03697408?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03697408 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Classical Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03697408's enrollment target sits among peer trials
23 4th of 8 higher than 5 of 8 other Classical Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Classical Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
RECRUITING · Phase 1
-
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
RECRUITING · Phase 1
-
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
RECRUITING · Phase 1
-
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Phase Ib of L-NMMA and Pembrolizumab
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI